An attempt by the British Generic Manufacturers Association (BGMA) to get a seat at the negotiation table for the new Voluntary Scheme for Branded Medicines Pricing and Ac
The UK’s voluntary system of revenue rebates to limit rises in medicines spending is already causing deep upset among branded drug manufacturers as clawbacks rise.
The 2019 Voluntary Scheme for Branded Medicines Access and Pricing (VPAS) saw the industry agreeing to make payments to the Department of Health and Social Care (DHSC).
As a successor to the 2019 Voluntary Scheme for Branded Medicines Access and Pricing is being negotiated, Leela Barham asks where rebates should go in future - that is, if rebates remain at